Artificial Intelligence Integration in Healthcare Prior Authorization: Promises, Perils, and the Evolving Landscape of Policy and Patient Care

The United States government is currently piloting an ambitious program leveraging artificial intelligence (AI) to streamline insurance-coverage decisions, specifically within the contentious realm of prior authorization for healthcare services. This initiative, while framed as a move toward greater efficiency and reduced waste, has ignited a fervent debate among healthcare providers, patient advocates, and policymakers, raising critical questions about the balance between technological advancement, cost containment, and patient access to medically necessary care. The core of this discussion revolves around whether AI will truly expedite valid claims and alleviate the administrative burden, or if it risks exacerbating existing challenges, leading to an increase in wrongful denials and potentially compromising patient health outcomes.

The Prior Authorization Conundrum: A System Under Scrutiny

For many Americans, the process of obtaining pre-approval for medical care recommended by their physicians is a frustrating and often debilitating ordeal. Personal anecdotes abound, painting a vivid picture of patients and their families navigating intricate bureaucratic labyrinths to secure coverage for essential prescription medications, critical medical procedures, and various other health services. This process, formally known as prior authorization, requires healthcare providers to obtain approval from insurers before rendering certain services, ostensibly to ensure medical necessity and prevent overuse or expenditure on services with less costly alternatives.

While proponents argue that judicious prior authorization acts as a crucial check on healthcare spending and inappropriate care, a significant majority of physicians express profound concerns. Surveys consistently highlight that prior authorization frequently leads to care delays, which can compel patients to abandon recommended treatments while awaiting insurers’ verification of eligibility and medical necessity. For instance, a 2025 American Medical Association (AMA) survey of physicians revealed widespread dissatisfaction, with doctors voicing concerns about how these delays negatively impact patient health. Patients facing denials have the option to appeal, but this recourse introduces further delays, often at critical junctures in their treatment. The cumulative effect of these administrative hurdles is a system perceived by the public as a major burden, as evidenced by a KFF poll where prior authorizations ranked as one of the public’s biggest healthcare frustrations.

The scale of this challenge is substantial. In Medicare Advantage, the privately run alternative to original Medicare that now covers approximately 55 percent of Medicare-eligible seniors and disabled individuals, insurers issue millions of full or partial claim denials annually based on prior authorization. Federal government reports, including those released in June of the current year, have documented instances where plans, including the three largest Medicare Advantage organizations, have rejected requests for skilled nursing and rehabilitation admissions at alarmingly high rates, sometimes even when coverage rules were seemingly met. Such obstacles to medically appropriate care are a particular area of concern, prompting scrutiny from oversight bodies like the HHS Office of Inspector General (OIG).

A newly released Commonwealth Fund survey further underscored the pervasive nature of these denials. In 2025, roughly one in five American working-age adults with private insurance reported that they or a family member had been denied coverage for physician-recommended medical care. The consequences are stark: 41 percent of those who experienced a prior authorization denial reported delayed care, and more than a quarter indicated that their health problem worsened as a direct result. NBC News has previously reported on patients "stuck in prior authorization purgatory," running out of time or viable treatment options while caught in the bureaucratic mire.

The Promise and Peril of AI in Prior Authorization

Against this backdrop, the advent of artificial intelligence offers both a glimmer of hope and a shadow of apprehension. With its unparalleled capacity to process and analyze vast quantities of information with speed and precision, AI could theoretically expedite the approval of unambiguously allowable claims, thereby reducing care delays and freeing up human resources. The idea is that AI could quickly identify routine requests that clearly meet clinical guidelines, allowing human reviewers to focus on more complex or nuanced cases.

However, the integration of AI-driven prior authorization is not without its detractors. Significant resistance stems from the fear that AI, if not carefully implemented and overseen, could lead to an increase in wrongful denials of health insurance coverage. The 2025 AMA survey of physicians, for instance, highlighted substantial concern regarding the application of AI tools, with a striking 61 percent of doctors worrying that AI would exacerbate denials of treatments they deem medically necessary. Health policy analyst Camm Epstein succinctly articulated this sentiment in an email to Undark, stating that "AI should be used to make appropriate care easier to approve, not necessary care easier to deny." This concern is amplified by the potential for opaque algorithms and a lack of transparency in AI’s decision-making processes. The AMA advocates for requiring insurers to provide detailed clinical reasoning to justify denials of coverage, in addition to demanding greater transparency regarding the underlying AI algorithms.

The WISeR Model: A Government Pilot Program

The Trump administration has launched a specific pilot program to test the efficacy and impact of AI in this domain. This year, the Centers for Medicare and Medicaid Services (CMS) initiated a demonstration project known as WISeR, or the Wasteful and Inappropriate Service Reduction Model. Operating in six states and slated to run through December 2031, WISeR’s primary objective is to reduce waste and fraud within original Medicare by decreasing unnecessary procedures. The model integrates advanced technologies such as machine learning with human clinical review to evaluate services identified as potentially vulnerable to overuse, fraud, and abuse. Examples of targeted services include skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for knee osteoarthritis.

The introduction of prior authorization, particularly one driven by AI, into original Medicare represents a significant policy shift. While prior authorization has been extensively utilized in Medicare Advantage, its deployment in original Medicare has historically been rare. This shift has raised eyebrows among patient advocates and healthcare providers who fear it may not be beneficial for patients. An OIG memorandum published in 2022, prior to WISeR’s implementation, had already highlighted that Medicare Advantage plans denied beneficiaries’ access to services in over one in ten instances, even when those services appeared to meet coverage rules. While many of these denials were overturned upon appeal (in 2024, Medicare Advantage plans overturned 81 percent of denials), the initial denial itself creates a significant barrier and delay to care.

Critics of WISeR, including health insurance reform advocate Wendell Potter and Zena Wolf of the Center for Health & Democracy, have voiced strong concerns. They point to investigations by reputable news organizations, which suggest that in the initial months of the pilot program, WISeR has already caused delays in care and denials in some instances across the six participating states. Furthermore, despite the promise of automated processes, the introduction of AI-driven prior authorization can impose a high administrative burden on healthcare providers, who must then dedicate additional resources to addressing denials and appeals.

A particularly contentious aspect of the WISeR model is the financial incentive structure for participating vendors. These vendors, hired to execute the AI-driven prior authorization, earn a share of what CMS terms "averted expenditures." This mechanism directly links vendor revenue to the prevention of payments for services, raising long-standing concerns about profit-making based on discouraging or denying medically necessary care. Several lawmakers have responded to these concerns by introducing resolutions and amendments aimed at blocking funding for the WISeR model, citing potential threats to patient access.

A Bifurcated Stance: Policy Paradoxes

Interestingly, the Trump administration appears to hold a bifurcated view on prior authorization. While CMS expands its use within original Medicare through AI initiatives like WISeR, the agency simultaneously advocates for lessening and streamlining its application by private insurers, including Medicare Advantage plans. CMS Administrator Mehmet Oz has publicly warned insurance company executives that they must ease the burden of prior authorization or face federal regulation. "If you don’t do it yourselves, then we’re going to do it for you," Oz reportedly stated, indicating a clear intent to intervene if the industry does not self-correct.

In response to this pressure and possibly to preempt further executive action or legislative intervention, health plans have recently released data suggesting compliance with administration demands. An industry-based survey revealed that between June 2025 and April 2026, requests for prior authorization declined by 11 percent. However, a crucial piece of information remains unknown: whether the rate of denials has also decreased. Without this transparency, the true impact of this reduction in requests on patient access remains unclear. In a separate survey conducted last year, all responding health plans affirmed that "AI or algorithms without clinician or practitioner review are not used to deny prior authorization requests that involve medical necessity or clinical considerations." Furthermore, insurers pledged to enhance transparency regarding the clinical reasoning underpinning prior authorization decisions. While these commitments may assuage some concerns about the lack of human oversight in AI-driven decisions, placating critics and rebuilding trust will undoubtedly be an arduous task.

Broader Implications and the Path Forward

The integration of AI into healthcare prior authorization underscores a fundamental tension within the American healthcare system: the desire for cost control and efficiency versus the imperative of patient access and quality of care. The potential for AI to introduce bias, perpetuate existing inequities, or err in complex medical judgments adds an ethical layer to the debate. Ensuring that AI algorithms are transparent, auditable, and free from discriminatory biases is paramount. Without robust oversight and clear accountability mechanisms, there is a significant risk that AI could simply automate and accelerate a flawed system, rather than fundamentally improving it.

The calls for detailed clinical reasoning behind denials and greater transparency in AI algorithms are not merely technical demands; they are foundational to maintaining trust between patients, providers, and payers. The ongoing legislative efforts to scrutinize and potentially defund programs like WISeR reflect a deep-seated concern that the pursuit of efficiency must not come at the expense of patient well-being.

As Jared Dashevsky, a physician and founder of Healthcare Huddle, articulated, AI holds immense promise to "eliminate barriers, reduce administrative waste, give us more time with patients." However, he cautions that "that’s not what’s being built." Instead, he fears an "arms race to deny faster and appeal faster," leading to "more automation of a broken system that shouldn’t exist in its current form."

The future of AI in healthcare prior authorization will depend heavily on whether policymakers, insurers, and technology developers can collectively steer its application toward genuinely improving patient care and reducing administrative friction, rather than creating new barriers. The current landscape is one of innovation meeting intense skepticism, a dynamic that will undoubtedly shape the accessibility and quality of healthcare for millions of Americans in the years to come. The challenge lies in harnessing AI’s power to serve, not supersede, the fundamental goal of a patient-centered healthcare system.